Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Real world experience of switching from tralokinumab to lebrikizumab: Author's reply. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - "The availability of lebrikizumab as treatment for patients with severe AD would result in cost savings for Italy. Given the paucity of economic data on lebrikizumab, new economic studies should be conducted to confirm these findings."

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Tacrolimus Ophthalmic Suspension Can Be an Effective Treatment Option for Biologic-Induced Refractory Conjunctivitis. (PubMed, Cureus) - "The disease is primarily driven by Th2-associated cytokines such as interleukin (IL)-4, IL-13, and IL-31, which contribute to inflammation and exacerbate pruritus, perpetuating the "itch-scratch cycle." Recently, biologics targeting Th2 cytokines - such as dupilumab, lebrikizumab, and tralokinumab - have emerged as effective treatment options for moderate-to-severe AD...Herein, we report a case of AD successfully controlled with lebrikizumab, in which the patient developed conjunctivitis refractory to artificial tears and fluorometholone eye drops. Switching to tacrolimus ophthalmic suspension resulted in marked improvement. While tacrolimus eye drops are not approved for conjunctivitis, they are indicated for vernal keratoconjunctivitis and may be considered in severe cases of AD-related conjunctivitis in consultation with ophthalmologists."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13

Effectiveness and safety of dupilumab versus tralokinumab in atopic dermatitis: A propensity score– matched analysis from the BioDay registry (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy (Yahoo Finance) - P3b | N=402 | ADHAND (NCT05958407) | Sponsor: LEO Pharma | "LEO Pharma A/S...announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis on the hands, who are candidates for systemic therapy....The trial met the primary endpoint and all secondary endpoints with a statistically significant improvement in atopic dermatitis on the hands after 16 weeks of treatment compared to placebo. The treatment was also generally well-tolerated, with no new safety signals identified. The majority of adverse events observed were non-serious, mild or moderate in severity. All of the signs and symptoms of atopic dermatitis on the hands were improved significantly early in the treatment period with tralokinumab compared to placebo."

P3 data • Atopic Dermatitis • Dermatitis

“Update of sections 4.8 and 5.1 of the SmPC in order to update clinical efficacy and safety information based on the final clinical trial report of the open-label extension PASS study LP0162-1337 (ECZTEND), listed as a category 3 study in the RMP.” (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 5 – 8 May 2025

PRAC • Atopic Dermatitis • Immunology

A Clinician's Guide to Dupilumab-related Ocular Surface Disease. (PubMed, J Clin Aesthet Dermatol) - "Current biologics approved for AD include dupilumab, an IL-4 receptor alpha inhibitor, tralokinumab, an IL-13 inhibitor, lebrikizumab, an IL-13 inhibitor, and nemolizumab, an IL-31 receptor alpha inhibitor. For practitioners, it is important to be aware that OSD is a relatively common side effect but rarely causes problems severe enough to lead to cessation of treatment. This brief report provides guidance on screening and managment of OSD in patients with AD receiving anti-IL-4 and/or IL-13 treatment."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13 • IL4 • IL4R

New Treatments in Atopic Dermatitis Update. (PubMed, Ann Allergy Asthma Immunol) - "Non-steroidal topical treatments, such as roflumilast and tapinarof creams, are approved for adults and children down to 6 and 2 years, respectively. Topical Janus kinase (JAK) inhibitors, including ruxolitinib, leverage inhibition of the JAK1 pathway with low concern for toxicity. The use of biologics targeting the interleukin (IL)-4/IL-13 pathway has expanded; dupilumab is approved for patients 6 months and older and tralokinumab and lebrikizumab are approved for 12 years and above. Most recently, nemolizumab, targeting the IL-31 receptor, which mediates nonhistaminergic itch, has been approved for those 12 years and above. Although baricitinib is approved in Europe and Japan, upadacitinib and abrocitinib remain the only oral JAK inhibitors approved for U.S. patients 12 years and older...These innovations represent a shift toward personalized AD management. As the treatment landscape evolves, ongoing research is essential to assess long-term safety and efficacy, as..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • IL13 • JAK1 • TNFSF4

Identifying Week 48 Delayed Responders to Tralokinumab in Real-World Practice for Japanese Patients with Moderate-to-Severe Atopic Dermatitis. (PubMed, Dermatitis) - "Compared with poor responders, delayed responders had lower proportions of males and prior systemic therapy, and lower baseline values of thymus and activation-regulated chemokine (TARC) and lactate dehydrogenase (LDH). Female sex, absence of prior systemic therapy, and lower baseline values of TARC and LDH may predict the week 48 delayed responders to tralokinumab in patients with AD."

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease. (PubMed, Clin Exp Allergy) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. (PubMed, Ann Allergy Asthma Immunol) - "Regardless of presence or number of self-reported atopic comorbidities, 16 weeks of tralokinumab treatment improved AD severity in adults and adolescents."

Journal • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Food Hypersensitivity • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • IL13

Real-world effectiveness of tralokinumab in adults with atopic dermatitis: physician-assessed severity after up to 9 months in the TRACE study (CDA 2025) - "Conclusions These results compliment those from phase 3 trials supporting the real-world effectiveness of tralokinumab in treating adults with moderate-to-severe AD. Improvements were progressive over 9 months even among those with previous dupilumab experience."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. (PubMed, J Clin Aesthet Dermatol) - "Importantly, all patients experienced resolution of arthralgia without recurrence while on tralokinumab. These findings support the use of tralokinumab as an effective and safe alternative therapy for patients with dupilumab-induced arthralgia."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Prurigo Nodularis • Pruritus • Rheumatology • IL13 • IL4

Real-world effectiveness of tralokinumab for head and neck atopic dermatitis after up to 9 months treatment in the TRACE study (CDA 2025) - "Similar improvements were observed across all endpoints in dupilumab-naïve and dupilumab-experienced patients. Conclusions Up to 9 months of tralokinumab treatment improved disease severity and quality of life in patients with AD in the difficult to treat H&N area, regardless of prior dupilumab use."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Reply to 'Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis'. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis. (PubMed, JAAD Case Rep) - No abstract available

Journal • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Real-world effectiveness of tralokinumab for atopic dermatitis with genital involvement: Outcomes after 3 months of treatment in the TRACE study (CDA 2025) - "Conclusions Awareness of the impact of genital involvement in AD and the effectiveness of available treatments are crucial for making informed decisions. These 3-month results demonstrate real world effectiveness of tralokinumab in AD patients with genital involvement."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series. (PubMed, Int J Dermatol) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Corneal Perforation Associated With Tralokinumab. (PubMed, Cornea) - "This case represents the first reported instance of corneal perforation potentially related to tralokinumab. Although ocular side effects of IL-13-targeted therapies are typically mild, this report highlights the possibility of severe complications. Given the increasing use of biologic agents in dermatology, awareness of rare but potentially vision-threatening adverse effects is essential. In suspected cases, early ophthalmologic evaluation and multidisciplinary management are crucial for preventing poor outcomes in patients receiving tralokinumab."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Keratitis • Mood Disorders • Ocular Inflammation • Ophthalmology • IL13

Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment (EAACI 2025) - "Inhibition of these cytokines by antibodies, including Dupilumab, Tralokinumab and Benralizumab have yeilded highly effective therapeutics for allergies and asthma, however they are limited by the inherent properties of antibody based therapeutics, notably high costs of production, invasive administration and possible immunological side effects. These peptides currently possess high concentrations for the effect, however with sequence studying and optimisation these can be greatly improved. This study proves that peptides can inhibit cytokine signalling and lays the foundation for future development of smaller, less invasive and easier to produce cytokine inhibitor therapeutics."

Allergy • Immunology • IL13 • IL4 • IL4R

TARC levels in patients with atopic dermatitis: a marker for clinical improvement following sublingual immunotherapy? (EAACI 2025) - "Background Thymus-and activation-regulated chemokine (TARC) has been identified as a biomarker for Atopic Dermatitis (AD) and has been shown to decrease after therapy with Dupilumab and Tralokinumab. Conclusion Our data confirmed that TARC levels were useful in indicating a decrease in disease activity in AD. However, we were not able to demonstrate that addition of HDM-SLIT to the therapeutic regimen in HDM allergic patients with AD would result in further decrease of TARC levels."

Clinical • IO biomarker • Late-breaking abstract • Atopic Dermatitis • Dermatitis • Immunology

Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment (EAACI 2025) - "Inhibition of these cytokines by antibodies, including Dupilumab, Tralokinumab and Benralizumab have yeilded highly effective therapeutics for allergies and asthma, however they are limited by the inherent properties of antibody based therapeutics, notably high costs of production, invasive administration and possible immunological side effects. These peptides currently possess high concentrations for the effect, however with sequence studying and optimisation these can be greatly improved. This study proves that peptides can inhibit cytokine signalling and lays the foundation for future development of smaller, less invasive and easier to produce cytokine inhibitor therapeutics."

Late-breaking abstract • Allergy • Immunology • IL13 • IL4 • IL4R

Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD. (PubMed, Dermatitis) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study. (PubMed, Dermatol Ther (Heidelb)) - "This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib's superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Cardiovascular • Conjunctivitis • Dermatitis • Dermatology • Hematological Disorders • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study. (PubMed, Dermatol Ther (Heidelb)) - "This large case series provides RWE building on tralokinumab clinical trial data and highlights the potential rapid and long-term response in patients with AD irrespective of their Fitzpatrick skin type or treatment history, including patients previously treated with dupilumab."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation